Kee Pharma Limited is a well-established Delhi based pharmaceutical company that was started in 1957 by Mr. C.R. Motihar. Today, KPL has a 300 strong work force that is made up of professional and dynamic individuals working together as a team to ensure that KPL is an efficient and professionally run organisation.

Kee Pharma is an Innovative, Dynamic and Caring organisation. We strive to provide the best that modern medicine has to offer be it new dosage forms, revolutionary pharmaceutical molecules or biotechnologically engineered cures. Innovative attitude to life drives us to always look for a better and more effective cure. Our Dynamism allows us to cross our nation’s boundaries and forage into the global market to find these cures. Our Caring outlook makes us ensure that these cures are available to the people of India through an effective and extensive distribution network and careful pricing. Being a well-established 45-year-old company, we have our feet firmly planted on the ground. We know the importance of Quality, Purity and Effectiveness of medicine. Above all else, we know what it takes to achieve all three and we make sure that we do Every person at Kee Pharma understands the importance of quality, purity and effectiveness and in this understanding, knows at the very bottom of his or her heart that - Life matters…People matter

1. Kee Pharma – This is the oldest division of the company which deals mainly in prescription and life saving drugs. In this division, the doctor segments that are visited and to whom the products are promoted are the Gynaecological, Orthopaedic, Dentist, Surgeon and General Practitioner segments. Hence the entire range of Kee Pharma’s products is aimed at these three segments of doctors, thus enabling us to concentrate our efforts and provide these segments with the best and latest in allopathic healthcare. The products that are promoted in this division are Revici Inj., Salsol and Diser.




2. Kee Biogenetics – KPL felt the need to introduce safer and more efficient treatments for life threatening diseases and conditions. The company felt that biogenetics, being the future of modern medicine would be able to provide new and sometimes improved cures to treat existing illnesses. Keeping this objective in mind, Kee Biogenetics was launched in 1999. This division was launched with two products –

1 Melagenina Plus– means substance generating melanin, pigment which colours skin. Melagenina is lipoprotein of low molecular weight by nature, stimulating the synthesis of melanocytes, which produce melanin.

2 Realfa 2B – a Recombinant Interferon which is mainly indicated in Oncology and Gastroenterology (Hepatitis B and Hepatitis C) Kee Biogenetics is constantly exploring the global pharmaceutical market for new and revolutionary products. At present we are very excited about the imminent launch of Erythropoietin and Heparin (Delta and Enoxi).

To us at Kee Pharma, providing quality healthcare is of utmost importance and we have taken our quality assurance department to the highest level of efficiency possible. Over the years, KPL has established itself in the Indian Pharma market as a company that is reliable, safe and above all else, committed to producing only the highest quality drugs. Apart from conforming to the FDA’s Primary regulations such as CGMP & Standards of Compendia’s, our manufacturing facilities also confirms to stricts WHO GMP regulations and holds a license for the same. In addition to these stringent  & standard regulations,our Quality Assurance  Departments has developed exhaustive methods to ensure the Quality, Safety, Purity and Effectiveness of the pharmaceutical dosage forms being manufactured by us.

At present KeePharma is looking forward to opening a new  production facility which is currently under development as per the revised schedule (CGMP). This production unit will have state of the art equipments and will follow  the latest manufacturing techniques for the in-house production of Oral and Parenteral dosage forms. On the export front, Kee Pharma is in the process of registering it’s drugs in SriLanka, Nepal, Iraq & Bangladesh and we are confident that we will have our products available in these markets by the end of the year 2005.